Relay Therapeutics, Inc. Common Stock
RLAY Real Time Price USDRecent trades of RLAY by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Daniel S. Goldman House / D | Sale $1,001 - $15,000 | Jul. 12, 2023 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by RLAY's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof Nov. 12, 2024
-
Patent Title: Shp2 phosphatase inhibitors and methods of use thereof Sep. 10, 2024
-
Patent Title: Shp2 phosphatase inhibitors and methods of making and using the same Feb. 06, 2024
-
Patent Title: Fgfr inhibitors and methods of use thereof Oct. 10, 2023
-
Patent Title: Shp2 phosphatase inhibitors and methods of use thereof Dec. 20, 2022
-
Patent Title: Shp2 phosphatase inhibitors and methods of use thereof Mar. 02, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of RLAY in WallStreetBets Daily Discussion
Recent insights relating to RLAY
Recent picks made for RLAY stock on CNBC
ETFs with the largest estimated holdings in RLAY
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RLAY Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.